Editas Medicine (EDIT) Projected to Post Earnings on Wednesday

Editas Medicine (NASDAQ:EDIT - Get Free Report) is anticipated to release its earnings data before the market opens on Wednesday, March 5th. Analysts expect Editas Medicine to post earnings of ($0.39) per share and revenue of $37.17 million for the quarter.

Editas Medicine Stock Down 0.5 %

Shares of NASDAQ:EDIT traded down $0.01 during trading on Thursday, hitting $1.83. The stock had a trading volume of 7,768,495 shares, compared to its average volume of 4,652,667. The stock has a market capitalization of $151.06 million, a price-to-earnings ratio of -0.71 and a beta of 1.94. Editas Medicine has a 12-month low of $1.12 and a 12-month high of $11.58. The stock has a 50-day simple moving average of $1.40 and a two-hundred day simple moving average of $2.52.

Wall Street Analysts Forecast Growth

EDIT has been the topic of several analyst reports. Truist Financial lowered Editas Medicine from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Robert W. Baird dropped their price objective on Editas Medicine from $10.00 to $8.00 and set an "outperform" rating on the stock in a report on Friday, December 13th. Chardan Capital reissued a "neutral" rating on shares of Editas Medicine in a report on Friday, December 13th. Barclays dropped their price objective on Editas Medicine from $5.00 to $3.00 and set an "equal weight" rating on the stock in a report on Friday, December 13th. Finally, Royal Bank of Canada dropped their target price on shares of Editas Medicine from $5.00 to $4.00 and set a "sector perform" rating on the stock in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, Editas Medicine currently has a consensus rating of "Hold" and an average target price of $7.00.

Remove Ads

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.